Kinetics of B Cell Response in Infants Menjugate Vaccination

A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00310700

Enrollment

Registered

2006-04-04

Start date

2005-05-31

Completion date

2005-11-30

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of Meningococcal Infection

Keywords

Prevention of Meningococcal Meningitis, vaccines, conjugate, immunology, infant, antibody persistence

Brief summary

Kinetics of B cell response in infants Menjugate vaccination

Interventions

BIOLOGICALMeningococcal C conjugate vaccine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

8 Weeks to 11 Weeks

Healthy volunteers

Yes

Inclusion criteria

* healthy infants

Exclusion criteria

* previously ascertained or suspected disease caused by N. meningitidis * previous household contact with an individual with a positive culture of N. meningitidis serogroup C

Design outcomes

Primary

Measure	Time frame
To establish at which day meningococcal C specific B cells are detectable in the blood of healthy infants following first and third immunisation with MenC Conjugate Vaccine as determined by Men C specific B-cell ELISPot assay.	—

Secondary

Measure	Time frame
To establish how long the B cells persist in the blood	—
To note the difference between plasma cell response following the first and third MenC vaccination.	—
To determine the immune response to Neisseria meningitidis serogroup C 26-34 days after the third immunisation	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026